PV-10

Phase 3Small molecule

PProvectus Biopharmaceuticals, Inc.

PV-10 is one of 151 small molecule programs targeting Cutaneous Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous MelanomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Breast CarcinomaActive, not recruiting

MelanomaActive, not recruiting

Cutaneous MelanomaPhase 3

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Breast CarcinomaPhase 1

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

21 2

Tecentriq

Roche

Phase 3

11 3

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 4

Libtayo

Regeneron

Phase 3

6 5

Imjudo

AstraZeneca

Phase 3

2 6

Tuoyi

SSun Yat-sen University

Phase 3

4 7

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Epacadostat

1 10

PV-10

PProvectus Biopharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Melanoma3 trials

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Unknown status·PProvectus Biopharmaceuticals, Inc.·Phase 1/2·NCT02557321·50 enrolled

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Completed·PProvectus Pharmaceuticals·Phase 2·NCT00521053·80 enrolled

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Completed·PProvectus Pharmaceuticals·Phase 1·NCT00219843·20 enrolled

Melanoma1 trial

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01760499·15 enrolled

Cutaneous Tumors1 trial

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

No longer available·PProvectus Biopharmaceuticals, Inc.··NCT01260779

Breast Carcinoma1 trial

PV-10 Chemoablation of Recurrent Breast Carcinoma

Completed·PProvectus Pharmaceuticals·Phase 1·NCT00237354·15 enrolled

Cutaneous Melanoma1 trial

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Terminated·PProvectus Biopharmaceuticals, Inc.·Phase 3·NCT02288897·20 enrolled

1 more indication

Ablation1 trial

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Unknown status·PProvectus Biopharmaceuticals, Inc.·Phase 1·NCT00986661·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for PV-10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PV-10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PV-10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Provectus Biopharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PProvectus Biopharmaceuticals, Inc.

PV-10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Melanoma3 trials

Melanoma1 trial

Cutaneous Tumors1 trial

Breast Carcinoma1 trial

Cutaneous Melanoma1 trial

Ablation1 trial

References

Drug Info

Quick Facts

Related News